Macleods Pharmaceuticals has received final approval from the US FDA for its generic Metformin Hydrochloride tablet salts, a product identified by ANDA206955, which is anticipated to intensify price competition in the oral hypoglycemic market. This development bolsters the company’s portfolio and allows it to capitalize as major brand-name drugs face increasing generic substitution.